BioSpace News Archive

Ascentage Pharma announced that 4 of its abstracts were selected for presentations at the 2023 American Society of Clinical Oncology Annual Meeting.

Human Immunology Biosciences (HI-Bio™) today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation (ODD) for felzartamab, the company’s investigational agent that is in development for the treatment of primary membranous nephropathy (PMN).

Convergent Therapeutics Inc., a clinical-stage biotechnology company focused on the development of next-generation radiopharmaceuticals for the treatment of cancer, today announced the title of an upcoming poster presentation on its lead asset, CONV01-α (225Ac-J591), a prostate-specific membrane antigen (PSMA)-targeted monoclonal antibody linked to actinium-225 (225Ac) at the American Society of Clinical Oncology Annual Meeting.

Harmony Biosciences Holdings, Inc. (“Harmony”) (Nasdaq: HRMY) today announced that its Phase 3 registrational INTUNE study evaluating the safety and efficacy of pitolisant in adult patients with idiopathic hypersomnia (IH) has completed enrollment nine months before its estimated enrollment completion date.

MindMed Publishes Report by Leading FDA Experts Validating MindMed’s MM-120 Drug Development Strategy Independent Third-Party Firm, Led by Former Senior FDA Officials, Calls Phase 2b Trial “Well-designed” and “Essential” Report Further Demonstrates that FCM’s Proposal to Skip Phase 2 for MM-120 – a Cornerstone of its Plan – is Unrealistic and Would Put MindMed Shareholders’ Investments at Risk Visit www.ProtectMindMed.com for More Information NEW YOR

Cartography Biosciences, an immuno-oncology company creating biologic therapies against novel targets guided by the first-ever comprehensive antigen atlas, announced the appointment of Blaine Templeman as Chief Administrative and Legal Officer.

Quantum-Si Incorporated, The Protein Sequencing CompanyTM, announced that it will be participating in the Jefferies Healthcare Conference taking place at the Marriott Marquis, New York, NY on June 7-9, 2023.

POINT Biopharma Global Inc. (NASDAQ: PNT) (the “Company” or “POINT”), a company accelerating the discovery, development, and global access to life-changing radiopharmaceuticals, today announced an upcoming poster presentation for the Company’s ongoing phase 1, pan-cancer, fibroblast activation protein-α (FAP-α)-targeted trial, FRONTIER (NCT05432193), at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting.

Ascendis Pharma A/S announced the company will host an Oncology program update for the investment community on Wednesday, May 31, 2023 in New York from 10:00 a.m. to 12:00 p.m. Eastern Time.

Legend Biotech Corporation announced today that a Type II variation application was submitted to the European Medicines Agency (EMA) for CARVYKTI® based on data from the CARTITUDE-4 study (NCT04181827), which investigates the treatment of adult patients with relapsed and lenalidomide-refractory multiple myeloma who have received one to three prior lines of therapy.